Growth continues at Discovery Park as new tenants arrive
Psyros Diagnostics & VisusNano join innovation community
Sandwich, Kent, September 21 2020 – The innovation community is continuing to evolve at Discovery Park, the Life Sciences Opportunity Zone for ambitious and growing life sciences companies, as new tenants move in and others continue to develop. New entrants Psyros Diagnostics and VisusNano have both taken laboratory and office space at the Park.
StemFit® for Mesenchymal Stem Cells (MSC) is the latest addition to the StemFit® family of stem cell media. It is a chemically defined and human/animal origin free medium, optimized for the isolation and culture of MSCs from bone marrow (BM-MSC), umbilical cord (UC-MSC), and adipose (ADSC) under serum-free, human platelet lysate free conditions.
Pharmaceutical and biotech product development consultancy Boyds has recruited Kathryn Bartley as Senior Clinical Research Associate.
The appointment follows last year’s acquisition of Blue Duck Consultancy which fueled the expansion of Boyds’ in-house clinical and medical affairs services offering.
Kathryn has over 18 years’ experience in the industry, primarily in study and site management and monitoring. Her work has covered a variety of therapy areas across all trial phases within both the commercial and academic sectors.
Cambridge, UK, 08 September 2020: Metrion Biosciences Limited (Metrion), the specialist ion channel CRO and drug discovery company, today announced it has significantly enhanced its global business development capabilities, with additional resources now committed to support key regions in the USA, Europe and Japan.
Cambridge, UK, and Cambridge, MA, 08 September 2020: PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, and XtalPi Inc., a leading algorithm-driven artificial intelligence (AI)-based pharmaceutical technology company, today announced they have entered into a drug discovery collaboration agreement. Financial details are not disclosed.
CAMBRIDGE, UK 09 September 2020 – EVONETIX LTD (‘Evonetix’), the synthetic biology company developing a desktop platform for scalable, high-fidelity and rapid gene synthesis, today announced a collaboration with leading, global high-performance analog technology company, Analog Devices, Inc. The companies will work together on the advancement and commercial scale-up of Evonetix’s proprietary microelectromechanical systems (MEMS)-based silicon chips and accelerate the development of Evonetix’s first product, a DNA desktop writer.
Executive search consultancy, Horton International UK, has announced the appointment of Mark Johnson as Senior Partner of its Oxford-based Global Healthcare arm.
AMSBIO announce new additions and certifications for their market-leading range of clinical grade, chemically defined cryopreservation excipient solutions - STEM-CELLBANKER® and HSC-BANKER®.